Riskpilot← Back to searchSign inGet full accessHaksa Pharma AB
ABActiveOrg 5569090813StockholmLegal activities · NACE 6910Est. 20120 employees
Revenue 2025
SEK 0
EBITDA margin
—
+9% vs 2024
Equity ratio
91.3%
Financial strength
Net profit 2025
SEK -8K
+9% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -8K | +9% |
| Net profit | SEK -8K | +9% |
| Total assets | SEK 58K | -13% |
| Equity | SEK 53K | -14% |
| Employees | 0 | — |
Legal name
Haksa Pharma AB
Org number
5569090813
Legal form
Aktiebolag
NACE code
6910 · Legal activities
Founded
1 november 2012
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva marknadsföring, försäljning, distribution och förmedling av läkemedel samt därmed förenlig verksamhet.
Address
Stockholm
Phone
+46735334313
Email
sadik@guardadvokater.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 121 | 0 | 47 | 0 | 5 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 581 | 685 | −1 226 | 1 | −33 | 24 | −6 | −10 | −3 | −9 | −8 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — | — | — | — |
| EBIT | 581 | 685 | −1 226 | 1 | −33 | 24 | −6 | −10 | −3 | −9 | −8 |
| Net financials | — | — | −1 | — | — | — | — | 15 | — | — | — |
| Profit before tax | 441 | 586 | −987 | 1 | −33 | 24 | −6 | 5 | −3 | −9 | −8 |
| Tax | −101 | −74 | −0 | −0 | −0 | −0 | −0 | — | — | — | — |
| Net profit | 340 | 512 | −987 | 1 | −33 | 24 | −6 | 5 | −3 | −9 | −8 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2 151 | 2 874 | 3 448 | 487 | 161 | 166 | 160 | 79 | 75 | 66 | 58 |
| Equity | 386 | 898 | 61 | 62 | 50 | 74 | 68 | 73 | 70 | 61 | 53 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | — |
| Short-term debt | 1 625 | 1 736 | 3 387 | 425 | 111 | 93 | 93 | 6 | 5 | 5 | 5 |
| Total debt | 1 625 | 1 736 | 3 387 | 425 | 111 | 93 | 93 | 6 | 5 | 5 | 5 |
EBITDA margin
-824500.0%
This company
15.8%
Market median
-5218454% vs market
20152025
Equity ratio
91.3%
This company
38.2%
Market median
+139% vs market
20152025
Return on equity
-15.7%
This company
18.4%
Market median
-185% vs market
20152025
Net profit margin
-824500.0%
This company
8.1%
Market median
-10179112% vs market
20152025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152025
Debt / equity
0.10×
This company
0.62×
Market median
+84% vs market
20152025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RH Audit | Audit | 2020 | — | — |
FE Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Haksa Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Resul Hamurcu | Audit | 0 companies |
| Fatih Engin Akan | Chief Executive Officer | 0 companies |
| Sadik Kutlu | Board of Directors | 0 companies |
| Marija Ingrid Nyström | Chairman | 0 companies |
| Anders Gustav Karlsson | Deputy Board Member | 0 companies |